Title:
RECOMBINANT FUSION PROTEIN TARGETING CD47 AND PD-L1, AND PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/040667
Kind Code:
A1
Abstract:
Provided is a recombinant fusion protein, comprising a PD-L1 antibody or antibody fragment thereof. At least one paratope of the PD-L1 antibody or antibody fragment thereof is connected to an extracellular Ig-like domain of a signal regulatory protein (SIRP) by means of a linker at the N-terminus of a heavy chain or light chain constituting the paratope, wherein the recombinant fusion protein can simultaneously bind to CD47, PD-L1, and FcR. Also provided are a nucleic acid molecule encoding the recombinant fusion protein, an expression vector comprising the nucleic acid molecule, a method for preparing the recombinant fusion protein, and a use of the recombinant fusion protein for treating diseases related to overexpression of CD47 and/or PD-L1.
Inventors:
TIAN WENZHI (CN)
LI SONG (CN)
LI SONG (CN)
Application Number:
PCT/CN2022/116312
Publication Date:
March 23, 2023
Filing Date:
August 31, 2022
Export Citation:
Assignee:
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC (CN)
International Classes:
C07K19/00; A61K38/17; A61K39/395; A61P35/00; C12N5/10; C12N15/62; C12N15/85
Domestic Patent References:
| WO2020177733A1 | 2020-09-10 |
Foreign References:
| CN113773401A | 2021-12-10 | |||
| CN111278865A | 2020-06-12 | |||
| CN107857819A | 2018-03-30 | |||
| CN107459578A | 2017-12-12 | |||
| CN111763261A | 2020-10-13 | |||
| CN112125975A | 2020-12-25 | |||
| CN113321735A | 2021-08-31 |
Other References:
LIAN SHU, XIE RUIZHI, YE YUYING, LU YUSHENG, CHENG YUNLONG, XIE XIAODONG, LI SHUHUI, JIA LEE: "Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, vol. 9, no. 1, 14 December 2019 (2019-12-14), XP055884207, DOI: 10.1038/s41598-019-40241-1
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: